The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 18, 2025

Filed:

Dec. 11, 2018
Applicant:

Amgen Inc., Thousand Oaks, CA (US);

Inventors:

Chetan Goudar, Newbury Park, CA (US);

Rohini Deshpande, Camarillo, CA (US);

Natalia Gomez, Playa Vista, CA (US);

Hedieh Barkhordarian, Newbury Park, CA (US);

Yan Wang, Thousand Oaks, CA (US);

Assignee:

AMGEN INC., Thousand Oaks, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12M 1/00 (2006.01); C12N 5/00 (2006.01); B01F 101/44 (2022.01); C12M 3/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2809 (2013.01); C07K 16/2863 (2013.01); C07K 16/2878 (2013.01); C07K 16/3069 (2013.01); C12M 29/10 (2013.01); C12N 5/0018 (2013.01); B01F 2101/44 (2022.01); B01J 2219/00725 (2013.01); B01J 2219/2446 (2013.01); B01J 2219/2466 (2013.01); C07K 2317/14 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/94 (2013.01); C12M 3/00 (2013.01); C12M 21/00 (2013.01); C12N 2521/00 (2013.01);
Abstract

The present invention provides a continuous upstream manufacturing process for the production of bispecific antibody products, which comprise at least two binding domains. The process comprises at least the steps of (i) providing in a perfusion bioreactor at least one mammalian cell culture, which is capable of expressing the bispecific antibody product, (ii) growing the mammalian cell culture at a first perfusion rate until a set point viable cell density is reached, and (iii) maintaining perfusion culture at a second perfusion rate, wherein the bispecific antibody product concentration in the bioreactor is kept below a threshold value. The bispecific antibody product is then subject to subsequent downstream processing. Moreover, the invention provides a bispecific antibody product produced by the continuous upstream manufacturing process.


Find Patent Forward Citations

Loading…